Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

GLP-1 Medications Zepbound Wegovy GLP-1 Receptor Agonists Mounjaro GLP-1 Agonists Ozempic GLP-1 Drugs Tirzepatide Semaglutide

Off-Label GLP-1 Prescriptions Surge for U.S. Children Ages 8–11

The rise outpaces pediatric evidence, raising new questions about safety, long-term effects, equitable access

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Study Finds Common GLP‑1 Use and Misuse Among People With Eating Disorders

Penn Study Finds About 30% Lower Breast Cancer Rates Associated With GLP‑1 Use

Cigna Drops GLP-1 Weight-Loss Coverage for Its Employees

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

New Data Link GLP-1 Weight-Loss Drugs to Fewer Sick Days and Lower Disease Risks

Analysts Lift Eli Lilly Targets After Blowout Quarter and Foundayo Debut

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Brazil Overhauls Obesity Drug Guidance as FDA Approves Lilly’s Daily Pill

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

Lilly Urges Recall After Finding New Impurity in Compounded Tirzepatide With B12

Novo Nordisk to Cut U.S. List Prices for Wegovy, Ozempic and Rybelsus to $675 in 2027

Hims & Hers Shares Fall After Mixed Q4 and Soft Q1 Outlook as GLP‑1 Scrutiny Intensifies

Eli Lilly’s Q4 Beat and Bullish Outlook Give Way to Stock Drop on Low-Cost GLP-1 Pills

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs